GLP-1 receptor agonists have completely flipped the script on what we do in obesity care. Medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) aren't just another fad; they're clinical heavy hitters. To put it in perspective, tirzepatide patients in trials dropped an average of 20.9% of their body weight over 72 weeks. (2025 NEJM head-to-head trial: tirzepatide 20.2% vs semaglutide 13.7% weight loss at 72 weeks) Semaglutide isn't far behind at 14.9%. Compare that to the 3–5% we usually see with standard lifestyle programs alone, and you start to see why the medical community is buzzing. [1]
The mechanics of GLP-1 therapy
Think of GLP-1 (glucagon-like peptide-1) as the "fullness signal" your gut normally sends your brain after you eat. It nudges the pancreas to release insulin, keeps food in your stomach just a bit longer, and essentially tells your brain, "Hey, we're good here." For many folks struggling with obesity, that signal is actually blunted. By using these medications, we're effectively restoring that messenger at a steady, clinical level so your body finally gets the memo. [2]
Where it gets interesting is with tirzepatide—it’s a dual agonist. By hitting both GLP-1 and GIP receptors, it basically doubles down on the metabolic signaling, which is exactly why the head-to-head trials show it outperforming semaglutide for pure weight loss. [3]
What to expect on the scale
- Expect a steady 1–2 pound drop per week once we've dialed in your maintenance dose.
- You’ll likely notice that 'is it lunch yet?' feeling start to fade within the first week or two.
- Food noise—those constant, intrusive thoughts about your next meal—usually just shuts off.
- Most people see the most aggressive progress between months 3 and 9 before things naturally level out.
Dosing: we start low for a reason
These are weekly injections, and look—we titrate for a reason. Starting at a low dose is the best way to keep you from feeling like you have a 24-hour stomach bug. For semaglutide, we usually move from 0.25 mg up to 2.4 mg over about four months; tirzepatide goes from 2.5 mg toward 15 mg. We’ll watch your progress and tweak the timing because everyone's tolerance is different. [1]
Safety and the fine print
Usually, we’re looking at manageable stuff like nausea, a bit of constipation, or reflux—and honestly, that's usually just a sign we need to adjust the dose. Now, there are rare, serious risks like pancreatitis or gallbladder issues to keep on your radar. I won't prescribe these if you have a history of MEN2, medullary thyroid carcinoma, or if you've dealt with active pancreatitis in the past.
Why muscle mass matters here
If you just stop eating and do nothing else, you're going to lose muscle—sometimes up to 40% of your total weight loss will be lean mass. That’s a bad trade. In our clinic, we pair the GLP-1 with a serious focus on protein, resistance training, and occasionally sermorelin. We want you to lose the fat, not the engine that keeps your metabolism running.
The bottom line
These meds aren’t some magic shortcut for people who don't want to work—they’re tools that finally make the work possible. When we combine the right medication with expert oversight, it becomes the most powerful non-surgical option we’ve ever had for treating obesity.
Available across Florida
Reset My Vitality is a Florida-licensed telehealth practice. The treatments covered in this guide are available to patients statewide, with medication shipped directly to your door. Explore the program for your city:
- Weight Loss in Miami, FL
- Weight Loss in Miami Beach, FL
- Weight Loss in Fort Lauderdale, FL
- Weight Loss in West Palm Beach, FL
- Weight Loss in Boca Raton, FL
- Weight Loss in Orlando, FL
- Weight Loss in Tampa, FL
- Weight Loss in Jacksonville, FL
- Weight Loss in Naples, FL
Key Clinical Studies
A short, responsible summary of recent peer-reviewed research relevant to this topic. This is for education only, not medical advice.
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
New England Journal of Medicine · 2021
Key finding: In a randomized controlled trial, participants on semaglutide 2.4 mg weekly lost a mean of 14.9% of body weight at 68 weeks vs 2.4% on placebo, with 86% achieving at least 5% loss.
Why it matters: Establishes the efficacy of semaglutide for substantial, sustained weight loss when paired with lifestyle support.
View studyTirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
New England Journal of Medicine · 2022
Key finding: Participants on tirzepatide 15 mg lost up to 20.9% of body weight at 72 weeks vs 3.1% on placebo, with 91% achieving at least 5% loss.
Why it matters: Shows the strong average results possible with the dual GLP-1/GIP agonist tirzepatide for eligible patients.
View studyTwo-year effects of semaglutide in adults with overweight or obesity (STEP 5)
Nature Medicine · 2022
Key finding: A 104-week trial found mean weight loss of 15.2% with semaglutide vs 2.6% with placebo, with weight loss largely maintained over two years on treatment.
Why it matters: Demonstrates long-term durability of GLP-1 weight loss when therapy is continued under clinical supervision.
View studyScientific References
Peer-reviewed studies and reviews cited in this article.
- [1]Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025. View study
- [2]Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. View study
- [3]Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002. View study